IGC Pharma, Inc. IGC
AMEX
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -6.51% | 24.95% | -5.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -6.51% | 24.95% | -5.50% |
| Cost of Revenue | -- | -- | 14.86% | 70.31% | 6.54% |
| Gross Profit | -- | -- | -23.16% | -4.84% | -15.55% |
| SG&A Expenses | -- | -- | -38.92% | -46.74% | -40.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -17.64% | -29.64% | -26.35% |
| Operating Income | -- | -- | 18.95% | 35.02% | 29.02% |
| Income Before Tax | -- | -- | 48.72% | 52.33% | 45.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 48.72% | 52.33% | 45.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 48.72% | 52.33% | 45.22% |
| EBIT | -- | -- | 18.95% | 35.02% | 29.02% |
| EBITDA | -- | -- | 19.58% | 36.78% | 30.70% |
| EPS Basic | -- | -- | 58.49% | 61.74% | 56.69% |
| Normalized Basic EPS | -- | -- | 46.47% | 52.17% | 46.46% |
| EPS Diluted | -- | -- | 58.49% | 61.74% | 56.69% |
| Normalized Diluted EPS | -- | -- | 46.47% | 52.17% | 46.46% |
| Average Basic Shares Outstanding | -- | -- | 19.48% | 23.98% | 30.04% |
| Average Diluted Shares Outstanding | -- | -- | 19.48% | 23.98% | 30.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |